Pricing Log in Create free account

Vericel Corporation (VCEL) vs Zymeworks Inc. (ZYME)

Vericel Corporation and Zymeworks Inc. are both Biotechnology companies. Vericel Corporation is the larger, with a market value of $2.7B against $2.0B — 1.3× the size. Zymeworks Inc. has negative trailing earnings, so its P/E is not meaningful; Vericel Corporation trades at 77.8×. Vericel Corporation grew revenue faster over the last twelve months: 25.3% against −69.8%. Vericel Corporation has the higher net margin (10.3% vs −404.0%) and the higher return on invested capital (7.88% vs 0.00%). Across the 18 metrics below, Vericel Corporation leads on 16 and Zymeworks Inc. on 2.

Valuation

Metric VCEL ZYME Biotechnology median
P/E 77.80 n/m 10.26
P/S 8.11 56.80 9.18
P/B 6.84 26.24 2.05
Price to free cash flow 45.40 n/m 24.81
EV/EBITDA 79.14 n/m 0.65
EV/Sales 7.64 49.52 8.98
Earnings yield 1.29% (6.99%) (34.89%)
Free cash flow yield 2.20% (5.76%) (24.52%)

Profitability

Metric VCEL ZYME Biotechnology median
Gross margin 74.47% (246.66%) 65.16%
Operating margin 8.32% (418.99%) 0.00%
Net margin 10.27% (404.00%) 0.00%
Free cash flow margin 17.86% (324.68%) 0.00%
Return on equity 9.44% (72.31%) (50.12%)
Return on assets 6.86% (37.25%) (45.60%)
Return on invested capital 7.88% 0.00% 0.00%

Growth

Metric VCEL ZYME Biotechnology median
Revenue growth (TTM) 25.30% (69.78%) 6.26%
EPS growth (last fiscal year) 60.00% 33.33% 29.88%
Revenue growth, 5-year CAGR 17.34% 22.16% 9.75%
Net income growth, 5-year CAGR 41.97% 0.00% 0.00%

Health

Metric VCEL ZYME Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 5.13 6.32 4.89
Net debt to EBITDA (6.08) 2.81 1.01

Dividend

Metric VCEL ZYME Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric VCEL ZYME Biotechnology median
Market cap 2.65b 2.04b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack